JAGX

Jaguar Health

OVERVIEW: ABOUT THE JAGUAR HEALTH FAMILY OF COMPANIES

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial which has completed enrollment and dosing for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. In mid-August 2023, the last patient completed their final visit for the stage 1 primary endpoint treatment period - a major milestone for the study. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp., is focused on developing novel prescription medicines derived from plants for mental health indications.

KEY CONSIDERATIONS

- Mytesi (crofelemer), Jaguar's lead product, generates revenue as an FDA-approved plant-based prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, a specialty market opportunity.
- Late October 2023 data from trial, the Phase 3 OnTarget study, could support expanding crofelemer's label into chemotherapy-induced overactive bowel in cancer patients, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
- Crofelemer is being studied in short bowel syndrome and microvillus inclusion disease, rare diseases with orphan drug incentives, expecting proof-of-concept (POC) data in Q4 2023.
- Jaguar has FDA conditional approval for Canalevia®-CA1 (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea in dogs, a first-in-class drug.
- Jaguar aims to execute new partnerships in 2023 to extend commercial reach for crofelemer and drive revenue growth.

About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Important Safety Information About Canalevia®-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

See full Prescribing Information at Canalevia.com.

PIONEERING NOVEL GI MEDICINES

Jaguar Health develops novel prescription drugs sustainably derived from rainforest plants to treat gastrointestinal diseases.

DIVERSE PIPELINE

Jaguar has an extensive development pipeline for its key product crofelemer spanning from preclinical research to an approved product.

ORPHAN DRUG INCENTIVES

Crofelemer has received orphan drug designations from the FDA and EMA for two rare diseases, providing incentives.

GLOBAL MARKET POTENTIAL

Jaguar is pursuing crofelemer formulations that span from supportive care to potential disease-modifying products in high unmet need areas.

MENTAL HEALTH FOCUS

A joint venture named Magdalena Biosciences that Jaguar formed with Filament Health is developing plant-based prescription drug candidates for mental health conditions.

PARTNERSHIP STRATEGY

Jaguar is pursuing development of partnerships to extend crofelemer's commercial reach globally while retaining key rights.

CANINE OPPORTUNITY

Jaguar has FDA conditional approval for a crofelemer product to treat chemotherapy-induced diarrhea in dogs.

NOVEL PRESCRIPTION DRUGS FROM RAINFOREST PLANTS

Jaguar Health is pioneering the development of first-in-class prescription drugs derived sustainably from rainforest plants to treat gastrointestinal diseases. The company's lead product is Mytesi, an oral drug made from the *Croton lechleri* tree that is FDA-approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Beyond HIV-related diarrhea, Jaguar is conducting clinical trials to expand crofelemer into new indications. A Phase 3 study of crofelemer for preventing chemotherapy-induced overactive bowel (CIOB) has results expected in late October 2023. A significant proportion of patients undergoing cancer therapy experience CIOB - which includes symptoms such as chronic debilitating diarrhea (loose and/or watery stools), urgency, and bowel incontinence. Diarrhea has the potential to cause dehydration, and worsen fatigue and non-adherence to treatment in this population.

Positive data could support approval in this large potential market of cancer patients needing supportive care for CIOB. Jaguar is supporting investigator-initiated and physician-initiated Investigational New Drug (IND) proof-of-concept studies of crofelemer for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU and Middle East/North Africa (MENA) regions, with results expected before the end of 2023 and in 2024. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID, potentially in 2024, for these debilitating conditions.

The company's IND application for crofelemer for the treatment of MVID was activated by the FDA August 7, 2023, and crofelemer has been granted Orphan Drug Designation (ODD) by the FDA and the European Medicines Agency (EMA) for both MVID and SBS with intestinal failure. The ODD programs in the US and EU qualify sponsors to receive potential incentives to develop therapies for the diagnosis, prevention, or treatment of rare diseases or conditions.

Additionally, Jaguar has FDA conditional approval for Canalevia-CA1, the first drug to receive any type of pproval from the FDA to treat chemotherapy-induced diarrhea in dogs. Between 600,000 to 1.5 million dogs receive chemotherapy annually in the US, representing a sizable canine medicine opportunity.

To drive commercialization globally, Jaguar is pursuing development of new partnerships in 2023 while retaining key rights to crofelemer. The company is led by founder and CEO Lisa Conte, a veteran in plant-based drug development.

With multiple milestones upcoming across its pipeline, Jaguar aims to extablish crofelemer as a portfolio of approved treatments for debilitating gastrointestinal conditions. If successful, Jaguar's novel rainforest-sourced prescription drugs could fill major unmet medical needs for both human and animal patients worldwide.

$12 MILLION

2022 Net Revenue

1.9 MILLION

New US cancer cases/year

1 IN 4

Dogs will develop a tumor

10K TO 20K

SBS patients in the US

LEADERSHIP

LISA CONTE
FOUNDER & CEO

- 30+ YEARS OF INDUSTRY EXPERIENCE
- OBTAINED FIRST ANTI-SECRETORY HUMAN PRODUCT FDA APPROVAL
- BOARD OF DIRECTORS OF HEALING FOREST CONSERVANCY
- RAISED OVER $400MM

STEVEN KING, PHD
CHIEF SUSTAINABLE SUPPLY, EHNOBOTANICAL RESEARCH & IP OFFICER

- SERVED AS HEAD OF SUSTAINABLE SUPPLY, ETHNOBOTANICAL RESEARCH & IP: 1989-2020
- BOARD OF DIRECTOR OF HEALING FOREST CONSERVANCY
- PHD AND MS IN BIOLOGY FROM INSTITUTE OF ECONOMIC BOTANY AT NEW YORK BOTANICAL GARDEN AND CITY UNIVERSITY OF NEW YORK

PRAVIN CHATURVEDI, PHD
CHIEF SCIENTIFIC OFFICER, CHAIR OF SCIENTIFIC ADVISORY BOARD

- 25+ YEARS DRUG DEVELOPMENT EXPERIENCE
- CO-FOUNDED SCION, INDUS AND OCEANYX PHARMACEUTICALS
- SUCCESSFULLY DEVELOPED MYTESI (FIRST PIVOTAL ADAPTIVE DESIGN) AND 7 PHARMACEUTICAL PRODUCTS

CAROL LIZAK, MBA
CHIEF FINANCIAL OFFICER

- 20 YEARS CORPORATE CONTROLERSHIP AND FINANCIAL PLANNING AND ANALYSIS EXPERIENCE UNDER US GAAP & IFRS
- 10+ YEARS WITH PUBLIC COMPANIES INCLUDING FOREIGN SUBS
- 5 YEARS IN BIOPHARMA